Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.276
Neutral
RSI(14)
46.890
Neutral
STOCH(KDJ)(9,3,3)
13.918
Neutral
ATR(14)
0.532
High Vlolatility
CCI(14)
-99.280
Neutral
Williams %R
76.181
Sell
TRIX(12,20)
0.187
Sell
StochRSI(14)
93.650
Buy
Bolt Biotherapeutics Inc
BOLT5.770USD
+0.380+7.05%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
11.08MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Bolt Biotherapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Bolt Biotherapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 119 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 26.75.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bolt Biotherapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Bolt Biotherapeutics Inc Highlights
StrengthsRisks
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 34.23% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.69M.
Fairly Valued
The company’s latest PE is -0.26, at a medium 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 28.62K shares of this stock.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
26.750
Target Price
+395.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Bolt Biotherapeutics Inc is 6.75, ranking 219 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 2.17M, representing a year-over-year increase of 90.10%, while its net profit experienced a year-over-year increase of 52.93%.
Score
Financials
6.39
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.29
Operational Efficiency
2.98
Growth Potential
8.77
Shareholder Returns
7.31
Bolt Biotherapeutics Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Bolt Biotherapeutics Inc is 7.67, ranking 91 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.26, which is -97.07% below the recent high of -0.01 and -248.05% above the recent low of -0.90.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 119/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Bolt Biotherapeutics Inc is 6.80, ranking 326 out of 392 in the Biotechnology & Medical Research industry. The average price target is 13.50, with a high of 75.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
26.750
Target Price
+395.37%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Bolt Biotherapeutics Inc
BOLT
5
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Bolt Biotherapeutics Inc is 7.01, ranking 120 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.86 and the support level at 5.01, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
5.688
Buy
MA10
6.094
Sell
MA20
6.190
Sell
MA50
5.727
Buy
MA100
5.555
Buy
MA200
5.779
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Bolt Biotherapeutics Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 55.30%, representing a quarter-over-quarter decrease of 0.01%. The largest institutional shareholder is James Simons, holding a total of 28.62K shares, representing 1.49% of shares outstanding, with 82.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Bolt Biotherapeutics Inc is 2.82, ranking 195 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.92. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.92
VaR
+6.76%
240-Day Maximum Drawdown
+53.65%
240-Day Volatility
+95.39%
Return
Best Daily Return
60 days
+9.31%
120 days
+17.87%
5 years
+22.06%
Worst Daily Return
60 days
-8.88%
120 days
-12.37%
5 years
-55.81%
Sharpe Ratio
60 days
+1.08
120 days
+0.22
5 years
-0.91
Risk Assessment
Maximum Drawdown
240 days
+53.65%
3 years
+88.44%
5 years
+95.16%
Return-to-Drawdown Ratio
240 days
-0.76
3 years
-0.30
5 years
-0.16
Skewness
240 days
+0.50
3 years
-0.62
5 years
-1.42
Volatility
Realised Volatility
240 days
+95.39%
5 years
+162.25%
Standardised True Range
240 days
+8.45%
5 years
+15.56%
Downside Risk-Adjusted Return
120 days
+38.69%
240 days
+38.69%
Maximum Daily Upside Volatility
60 days
+55.61%
Maximum Daily Downside Volatility
60 days
+38.26%
Liquidity
Average Turnover Rate
60 days
+0.12%
120 days
+0.54%
5 years
--
Turnover Deviation
20 days
-91.87%
60 days
-72.04%
120 days
+23.54%
Peer Comparison
Biotechnology & Medical Research
Bolt Biotherapeutics Inc
BOLT
6.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
